# Efficacy and Safety Study of Benralizumab for Patients With Severe Nasal Polyposis

> **NCT03401229** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 413 (actual)

## Conditions studied

- Nasal Polyposis

## Interventions

- **BIOLOGICAL:** Benralizumab 30 mg SC + Mometasone Furoate
- **BIOLOGICAL:** Matching placebo SC + Mometasone Furoate

## Key facts

- **NCT ID:** NCT03401229
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-15
- **Primary completion:** 2020-07-31
- **Final completion:** 2020-07-31
- **Target enrollment:** 413 (ACTUAL)
- **Last updated:** 2021-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03401229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03401229, "Efficacy and Safety Study of Benralizumab for Patients With Severe Nasal Polyposis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03401229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*